Artielle ImmunoTherapeutics Company Profile

01:51 EST 15th December 2018 | BioPortfolio

News Articles [60 Associated News Articles listed on BioPortfolio]

IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics

This name reflects the company’s focus on advancing the science of cytokine-based immunotherapy for the treatment of a range of cancers. Brooklyn ImmunoTherapeutics general partner and board chair ...

Deals this week: OSE Immunotherapeutics, Tango Therapeutics, Provention Bio

OSE Immunotherapeutics has received global rights to autoimmune disease candidate FR104 from Janssen Biotech. The drug was licensed to Janssen...Read More... The post Deals this week: OSE Immunotherap...

OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi

Funding through the Eurostars European Programme, led in France by Bpifrance Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE) today announces that the Compan...

Janssen returns FR104 global rights to OSE Immunotherapeutics

Janssen Biotech has returned the global rights to its autoimmune disease asset, FR104, to French pharmaceutical company OSE Immunotherapeutics. Effective...Read More... The post Janssen returns FR104 ...

ProBioGen and Pionyr Immunotherapeutics initiate second collaboration

ProBioGen AG, a premier service and technology provider for complex therapeutic glycoproteins, andPionyr Immunotherapeutics, an immuno-oncology company which develops next generation antibody-based th...

OSE Immunotherapeutics (OSE) - Immunotherapy research engine

Edison Investment Research - Pharmaceutical & healthcare - OSE Immunotherapeutics : OSE Immunotherapeutics (OSE) is a drug developer that focuses on both oncology and immune disorders, with an R&D...

OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress

Basel, Oct. 29-31, 2018 OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) presented at the World Immunotherapy Congress held on Oct. 29-31, 2018 in Basel, Switzerland. Bernard...

2018 Competitor Analysis Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin –

DUBLIN–(BUSINESS WIRE)–The “Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin” report has been added to’...

Drugs and Medications [0 Results]


PubMed Articles [111 Associated PubMed Articles listed on BioPortfolio]

Recent developments with immunotherapy for hepatocellular carcinoma.

Immunotherapy is on the way to become the new standard of care for advanced hepatocellular carcinoma (HCC) worldwide. With higher rates of objective responses, and overall less side effects compared t...

Human Vaccines & Immunotherapeutics: News.

Human Vaccines & Immunotherapeutics: News.

Perspective: cancer vaccines in the era of immune checkpoint blockade.

Current excitement about cancer immunotherapy is the result of unprecedented clinical impact from immune checkpoint inhibitors, particularly those that target programmed death (PD)-1 and PD-ligand (L)...

Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives.

Glioblastoma is a highly aggressive neoplasm with an extremely poor prognosis. Despite maximal gross resection and chemoradiotherapy, these grade IV astrocytomas consistently recur. Glioblastoma cells...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

The investigators propose to evaluate cabozantinib in combination with durvalumab in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malig...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [24 Associated Companies listed on BioPortfolio]

Artielle ImmunoTherapeutics

Brooklyn ImmunoTherapeutics LLC

Brooklyn ImmunoTherapeutics (formerly IRX Therapeutics) is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single ag...

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...

Selexis SA and OSE Immunotherapeutics SA

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...

OSE Immunotherapeutics

More Information about "Artielle ImmunoTherapeutics" on BioPortfolio

We have published hundreds of Artielle ImmunoTherapeutics news stories on BioPortfolio along with dozens of Artielle ImmunoTherapeutics Clinical Trials and PubMed Articles about Artielle ImmunoTherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Artielle ImmunoTherapeutics Companies in our database. You can also find out about relevant Artielle ImmunoTherapeutics Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record